Cetuximab was approved as a targeted therapy for recurrent/metastatic HNSCC after the EXTREME study, targeting EGFR, but it has shown limited efficacy in the clinical setting [81,94,98]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.